Loading clinical trials...
Loading clinical trials...
A Randomized, Intra-patient, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Conditions
Interventions
PRN473 (SAR444727)
Placebo
Locations
12
United States
Collaborative Neuroscience Research-Site Number:8400004
Long Beach, California, United States
California Allergy & Asthma Medical Group-Site Number:8400008
Los Angeles, California, United States
Florida International Research Center-Site Number:8400017
Miami, Florida, United States
Lenus Research & Medical Group-Site Number:8400006
Sweetwater, Florida, United States
Clinical Research Trials of Florida, Inc-Site Number:8400013
Tampa, Florida, United States
Remington Davis Inc-Site Number:8400012
Columbus, Ohio, United States
Start Date
August 13, 2021
Primary Completion Date
December 28, 2022
Completion Date
December 28, 2022
Last Updated
September 10, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
Principia Biopharma, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions